Shingles Vaccine Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026

1. Shingles Vaccine Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018- 2026 Shingles Vaccine Market-Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018- 2026 Shingles Vaccine Market The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that afects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had chicken pox in the past is at the risk of developing shingles. According to the Center for Disease Control and Prevention (CDC), there are an estimated one million cases of shingles reported every year in the U.S. Moreover, CDC states that around one in every three people in the U.S. will develop shingles in their lifetime. The risk

2. of shingles increases with age, with most cases reported among people over 40 years old. This is mainly due to weakening of the immune system on account of increased stress and inadequate intake of essential nutrients to keep immunity strong. Symptoms include skin rashes, nerve pain, vision loss, chills, upset stomach, muscle weakness, skin infection, and scarring. Treatment for shingles includes antiviral medication—acyclovir, valacyclovir, and famciclovir. These medicines help shorten the length and alleviate the severity of the illness. Further, analgesics may help relieve the pain. Download PDF Brochure or Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-pdf/73 Shingles Vaccine Market Dynamics There is a safe and efective vaccines available for preventing shingles. The Zostavax vaccine licensed by Merck & Co., Inc. in 2006 is an efective vaccine against shingles. The vaccine is intended for use in population over 50 years of age. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% efective in people aged 60 to 69 years. The efectiveness reduces with increasing age i.e. to 41% for the 70–79 age group, and 18% for those 80 years of age and older. The vaccine was launched in the India market in February 2016, at half the price of the U.S. market. Zostavax, among the only shingles vaccine in the market, recorded sales of US$ 749 million in 2015. In October 2016, GlaxoSmithKline (GSK)—a global leader in vaccines market —filed for U.S. FDA approval for its shingles vaccine, Shingrix. Shingrix has demonstrated better outcomes than Zostavax in its clinical trials. The vaccine was 90% efcacious in people over 70 years of age. The overall efectiveness of the vaccine is found to be 97%. Its higher efectiveness even among elder group of people is projected to increase its adoption across the globe. The impressive trail results would put Shingrix in a strong competitive position in the global market, currently monopolized by

3. Zostavax. The company is reported to have filed for regulatory approvals in the Europe and Canada markets in 2016, followed by Japan in 2017. It is estimated that the sales of Shingrix would reach US$ 1 billion by 2021. Shingles vaccines market is witnessing rapid infux of newer and expensive products. The industry is consolidated in nature however, new entrants are expected to emerge in the near future. Browse Detail Report @ https://www.coherentmarketinsights.com/insight/request-customization/73 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm ofering actionrready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1r206r701r6702 Email:sales@coherentmarketinsights.com